Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs TG 4010 (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2018 According to a Transgene media release, results from the interim analysis of this study are expected in 2H 2018.
    • 13 Sep 2017 According to a Transgene media release, first results from this trial are expected in the beginning of 2018.
    • 13 Mar 2017 According to a Transgene media release, first results from the study could be expected from the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top